A new study reveals that the abortion pill mifepristone carries a rate of serious or life-threatening complications 22 times higher than what the U.S. Food and Drug Administration (FDA) and the drug’s manufacturer, Danco Laboratories, have claimed.
The study raises serious concerns about the safety of the dangerous abortion pill.
The analysis, described as the “largest known study of the abortion pill,” was conducted by Ethics and Public Policy Center President Ryan Anderson and Director of Data Analysis Jamie Bryan Hall.
The authors maintain this is the largest ever study of the abortion pill.
It examined insurance claims data from Medicaid, TRICARE, Medicare, the Department of Veterans Affairs, and private insurers, covering 865,727 mifepristone prescriptions dispensed to 692,873 women between 2017 and 2023.
According to the study, approximately 10.9% of these prescriptions—94,605 chemical abortions—resulted in “serious adverse events” such as emergency room visits, hemorrhages, sepsis, infections, or follow-up surgeries within 45 days of taking the drug. This rate starkly contrasts with the FDA’s reported complication rate, which pro-life advocates argue has been ...
